Click here to complete the interactive survey.
Once you submit your responses, you will be able to view all of your colleagues’ responses.
Michelle, 46, is a bank manager who was diagnosed with MS in 1996. She was initially treated with interferon-beta-1a 44 ug. She experienced ongoing clinical and radiological activity and was switched to natalizumab in 2013. She remained stable for seven years. In February 2020, Michelle noted that she used to be able to walk 2 km but could now only manage about 1 km. Her EDSS score showed no change over the past year. EDSS score was 3.0 (motor 2, cerebellar 2, sensory 2). She was started on 4-aminopyridine but obtained no benefit. Read More
Long-term treatment of multiple sclerosis with anti-CD20 therapies is associated with sustained efficacy and a favourable safety profile, according to new data presented at the American Academy of Neurology (AAN) annual meeting, held April 22-27 in Boston. The following summarizes some of the key data that were presented. Read More
Chitinase-3-like 1 (CHI3L1) is a glycoprotein produced by monocytes, microglia and activated astrocytes that has been proposed as a diagnostic and prognostic biomarker of progression in MS. A recent meta-analysis of 20 studies reported that CHI3L1 levels in CSF were strongly correlated with the clinical course (Floro et al. Neurol Neuroimmunol Neuroinflamm 2022;9:e1164). Levels were higher in converting clinically isolated syndrome (CIS) vs. non-converting CIS; in MS vs. CIS or healthy controls; and in PPMS vs. RRMS. Read More